Pfizer Gains on FDA Drug Approval

Steel stocks recover after recent sell-off; HealthSouth resolves Medicare billing issues; plus more of Friday's stocks in the news

The FDA grants Pfizer (PFE ) approval to market Lyrica for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.